Yogaratnam JZ, Laden G, Madden LA, Seymour AM, Guvendik L, Cowen M, Greenman J, Cale A, Griffin S, et al.
Cardiovascular revascularization medicine : including molecular interventions. Date of publication 2006 Jul 1;volume 7(3):146-54.
1. Cardiovasc Revasc Med. 2006 Jul-Sep;7(3):146-54.
Hyperbaric oxygen: a new drug in myocardial revascularization and protection?
Yogaratnam JZ(1), Laden G, Madden LA, Seymour AM, Guvendik L, Cowen M, Greenman
J, Cale A, Griffin S.
Author information:
(1)Department of Cardiothoracic Surgery, Castle Hill Hospital, Castle Road,
Cottingham HU16 5JQ, United Kingdom. jeysenzy@msn.com
Ischemia-reperfusion injury (IRI) occurs following coronary artery
revascularization. Reactive oxygen species (ROS) were initially thought to play a
role in the pathogenesis of this injury. However, the evidence for this is
inconclusive. Recent studies involving ischemic preconditioning have identified
ROS as potential mediators for the cardioprotective effects observed following
this technique. Furthermore, cardiac studies involving IRI and the use of
hyperbaric oxygen (HBO) have demonstrated the ability of HBO to induce
cardioprotection and to attenuate IRI. This review suggests the possible role for
HBO as a new drug in the arena of myocardial revascularization and cellular
protection. While there is mounting clinical evidence for this, a methodological
understanding of HBO's cellular mechanisms of actions appears to be lacking. As
such, this article attempts to draw the similarity between HBO and other
protective oxidative stress mechanisms and then to speculate in an evidence-based
manner its possible cellular mechanistic role as a drug via the generation of
ROS.
DOI: 10.1016/j.carrev.2006.04.006
PMID: 16945821 [Indexed for MEDLINE]
